Euroopa Liit -
eesti -
EMA (European Medicines Agency)
lorviqua
pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
Eesti -
eesti -
Adama
legacy® pro
adama - suspensioonikontsentraat - diflufenikaan + kloortoluroon + pendimetaliin - herbitsiidid
Eesti -
eesti -
Adama
banjo forte®
adama - suspensioonikontsentraat - dimetomorf + fluasinaam - fungitsiidid
Eesti -
eesti -
Adama
sultan® super
adama - suspensioonikontsentraat - kvinmerak + metasakloor - herbitsiidid
Eesti -
eesti -
Adama
trimmer® 50 sg
adama - vees dispergeeruvad graanulid - tribenuroon-metüül - herbitsiidid